Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Oxford BioDynamics proposes GBP7 million fundraise for EpiSwitch plans

Tue, 01st Aug 2023 18:16

(Alliance News) - Oxford BioDynamics PLC on Tuesday said it plans to raise GBP7 million via a placing, subscription and retail offer of new shares in the company.

The Oxford-based biotechnology firm focused on discovering and developing epigenetic biomarkers said it would place a minimum of 43.0 million new shares and direct subscriptions of up to 2.5 million new shares to raise gross proceeds of no less than GBP5 million at an issue price of 11 pence each.

This is alongside a retail offer of new shares to raise up to GBP2 million, also at the issue price. Shares in Oxford BioDynamics closed down 3.3% to 10.40 pence each in London on Tuesday.

Oxford BioDynamics said the fundraising will provide working capital to "support the commercial development, through continued investment in sales and marketing activities to grow adoption of EpiSwitch and spending to complete the validation, launch and initial sales and marketing support of [prostate screening EpiSwitch]".

The fundraising is conditional upon shareholder approval at a general meeting on August 18, among other things.

"We are pleased to announce the proposed fundraising today, securing the group's runway through and beyond the launch of our eagerly awaited prostate screening EpiSwitch test later in 2023. Both existing and new shareholders intend to participate in the fundraising, alongside directors and senior management from across the group," said Chief Executive Officer Jon Burrows.

"We are also pleased that the primary bid offer will enable new and existing retail shareholders to invest in this next exciting phase of OBD's development, on the same terms as institutional investors."

"With the whole OBD team, I look forward to supporting the continued growth of our flagship EpiSwitch CiRT test in the US and UK and working towards a successful commercial launch of the important PSE test to the market."

By Greg Rosenvinge, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

Related Shares

More News
18 Jun 2024 16:58

Oxford BioDynamics revenue up 49% in first half as test sales rise

(Alliance News) - Oxford BioDynamics PLC on Tuesday reported strong revenue growth on the back of the increased commercialisation of its EpiSwitch gen...

11 Jun 2024 16:01

UK earnings, trading statements calendar - next 7 days

4 Jun 2024 10:28

Oxford BioDynamics develops canine cancer test with 89% accuracy

(Alliance News) - Oxford BioDynamics PLC on Tuesday announced the development of a canine cancer diagnostic test based on its EpiSwitch non-invasive p...

23 May 2024 21:08

TRADING UPDATES: Celadon ships to US; Oxford BioDynamics-Goodbody pact

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

21 May 2024 14:06

Oxford BioDynamics to provide tests to largest UK charitable hospital

(Alliance News) - Oxford BioDynamics PLC on Tuesday announced a new partnership with The London Clinic.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.